Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan J Little

Showing results (181-190 of 200) with videos related to

Pageof 20
Sort By:
Vaccine|November 30, 2025
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccinationSharon E Frey, Lindsey R Baden, Hana M El Sahly, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
The Journal of Infectious Diseases|August 8, 2018
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical StudiesGolnaz Namazi, Jesse M Fajnzylber, Evgenia Aga, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
The Journal of Infectious Diseases|August 10, 2023
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
The New England Journal of Medicine|September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 VaccineAnn R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Pageof 20

Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
Vaccine|November 30, 2025
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccinationSharon E Frey, Lindsey R Baden, Hana M El Sahly, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
The Journal of Infectious Diseases|August 8, 2018
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical StudiesGolnaz Namazi, Jesse M Fajnzylber, Evgenia Aga, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
The Journal of Infectious Diseases|August 10, 2023
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
The New England Journal of Medicine|September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 VaccineAnn R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Pageof 20